Dasatinib anhydrous is used in chronic myeloid leukemia that is resistant or intolerable to treatment regimens including imatinib mesylate.
Dasatinib anhydrous is a protein kinase inhibitor that inhibits BCR-ABL kinase and SRC family kinases and many other selective oncogenic kinases, including c-KIT, ephrin (EPH) receptor kinase, and PDGFβ receptor, dasatinib anhydrous primarily treats adult patients with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) chronic, accelerated, and blast phase (acute granulosis and blast leaching) resistant to imatinib mesylate, or intolerance.
|Package details:||100g/bottle; 1kg/foil bag|
Suitable for treatment of chronic myeloid leukemia.
Fortunachem Provides Not Only Professional Chemical Products But Also Professional Help
Keeping you up-to-date with all the latest information, news, and events about Fortunachem!